Legal Disclaimer | Terms & Conditions of Sale | Contact Us | Sitemap
© SensaPharm Ltd
The Durham Genome Centre, Park House, Station Road, Lanchester, Co. Durham, UK, DH7 0EX
Tel: +44 (0) 191 543 9411 | Fax: +44 (0) 871 231 1282 | Email: neil@sensapharm.eu
Registered in England No. 05064784, VAT No. (GB) 847252808

Research

The company is actively engaged in research programmes, which are designed to develop new products and services.

 

Biomarker and microbiome research

We conduct research into the biomarkers and microbiology relevant to healing in the diabetic foot ulcer and have identified several novel bacterial species in the wound bed and are investigating their relevance.

We have also conducted proteomic work into biomarker expression patterns (e.g. MMPs) and have combined this with genomic data from our sister company, Complement Genomics Ltd in order to develop novel prognostic assays.

We have also identified relevant new biomarkers using both microarray and proteomics approaches and are moving into the validation phase

The company is part of a consortium led by the National Physical Laboratory, Teddington, which has been funded by Innovate UK and subsequently the National Institute for Health Research in order to develop a novel theranostic device, whereby we combine a novel gel-scaffold with a Lateral Flow Device to aid therapy.

 

Artemisinin (malaria) research

We have an active interest in chemometrics associated with growth of the key anti malaria plant Artemisia annua.

The company sponsored a PhD student at the University of Warwick under a CASE award (Dr John Suberu, now graduated). This project, with Professor Alexi Lapkin (now of the University of Cambridge) and Professor Guy Barker primarily examined the effect of components of Artemisia annua upon the crystallisation efficiency of artemisinin. This is a key industrial problem, where different manufacturers and different batches can yield substantially different amounts of artemisinin.

This collaboration has resulted in several published papers:

A.Lapkin, A. Walker, N. Sullivan, . Khambay, B. Mlambo, S. Chemat. Development of HPLC analytical protocols for quantification of artemisinin in biomass in and extracts. J. Pharm Biomed Anal. 49 (2009) p908-915

J. Suberu, L. Song, S. Slade, N. Sullivan, G. Barker, A. Lapkin. A rapid method for the determination of artemisinin and its biosynthetic precursors in Artemisia annua L. crude extracts.
 Journal of Pharmaceutical and Biomedical Analysis 84 (2013), p269-277

J. Suberu, A. Gorka; L. Jacobs; P. Roepe; N. Sullivan, G. Barker; A. Lapkin Anti-plasmodial polyvalent interactions in Artemisia annua L. aqueous extract - possible synergistic and resistance mechanisms. PLOS ONE November 2013, vol 8 issue 11, e80790

J.Suberu, P. Yamin, K. Leonhard, L. Song, N. Sullivan, G. Barker, Alexei Lapkin. The effect of O-methylated flavonoids and other co-metabolites on the crystallisation and purification of artemisinin. Journal of Biotechnology, 171 (2014), 25-33, JBiotec-D-13-01062R1

Comparative cytotoxicity of artemisinin and cisplatin and their interactions with chlorogenic acids in MCF7 breast cancer cells. J.Suberu, I. Romero-Canelon, N. Sullivan, Alexei Lapkin, G.C. Barker. Chem Med Chem, 9 (2014) DOI: 10.1002/cmdc.20140285